Literature DB >> 21922339

Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment.

P G Sanz1, C V García Méndez, A L Cueto, V B Silva, J C Walther, R A Diez, S Martins, R J Giannaula.   

Abstract

A patient with chronic inflammatory demyelinating polyradiculoneuropathy and systemic lupus erythematosus arising after rubella vaccination was initially treated with plasmapheresis, corticosteroids and intravenous immunoglobulins, with partial response. After shift to rituximab, most clinical symptoms improved markedly, emphasizing the possible role of this monoclonal antibody in conventional therapy-resistant cases.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21922339     DOI： 10.1007/s00296-011-2130-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  9 in total

Review 1.  Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force.

Authors: 
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

2.  Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy.

Authors:  Hye-Jung Kim; Cha-Gyun Jung; Mark A Jensen; Danuta Dukala; Betty Soliven
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

3.  Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Lara Sanvito; Anna Makowska; Norman Gregson; Raffaello Nemni; Richard A C Hughes
Journal:  Autoimmunity       Date:  2009       Impact factor: 2.815

Review 4.  Rituximab in autoimmune hematologic diseases: not just a matter of B cells.

Authors:  Roberto Stasi
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

5.  T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  P A Csurhes; A-A Sullivan; K Green; M P Pender; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

6.  Recurrences, vaccinations and long-term symptoms in GBS and CIDP.

Authors:  Krista Kuitwaard; Martine E Bos-Eyssen; Patricia H Blomkwist-Markens; Pieter A van Doorn
Journal:  J Peripher Nerv Syst       Date:  2009-12       Impact factor: 3.494

7.  The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement.

Authors:  E L Smith; R H Shmerling
Journal:  Lupus       Date:  1999       Impact factor: 2.911

8.  Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy.

Authors:  H R Inglis; P A Csurhes; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-08       Impact factor: 10.154

Review 9.  Current treatments of chronic immune-mediated demyelinating polyneuropathies.

Authors:  Thomas H Brannagan
Journal:  Muscle Nerve       Date:  2009-05       Impact factor: 3.217
  9 in total
  5 in total

1.  Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases.

Authors:  Daniele Velardo; Nilo Riva; Ubaldo Del Carro; Francesca Bianchi; Giancarlo Comi; Raffaella Fazio
Journal:  J Neurol       Date:  2017-03-23       Impact factor: 4.849

Review 2.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

Review 3.  Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Association With Concomitant Diseases: Identification and Management.

Authors:  Yan Chen; Xiangqi Tang
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 4.  Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside.

Authors:  Amanda C Peltier; Peter D Donofrio
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

5.  Rituximab as First-Line Therapy in Severe Lupus Erythematosus with Neuropsychiatric and Renal Involvement: A Case-Report and Review of the Literature.

Authors:  Andrea Angeletti; Olga Baraldi; Anna Laura Chiocchini; Giorgia Comai; Paolo Cravedi; Gaetano La Manna
Journal:  J Clin Case Rep       Date:  2017-10-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.